[go: up one dir, main page]

WO2013105101A8 - Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same - Google Patents

Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same Download PDF

Info

Publication number
WO2013105101A8
WO2013105101A8 PCT/IN2012/000154 IN2012000154W WO2013105101A8 WO 2013105101 A8 WO2013105101 A8 WO 2013105101A8 IN 2012000154 W IN2012000154 W IN 2012000154W WO 2013105101 A8 WO2013105101 A8 WO 2013105101A8
Authority
WO
WIPO (PCT)
Prior art keywords
lipid nanoparticles
solid lipid
preparing
same
amphiphilic drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2012/000154
Other languages
French (fr)
Other versions
WO2013105101A1 (en
Inventor
Indu Pal KAUR
Rohit BHANDARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Department of Biotechnology of Ministry of Science and Technology India
Panjab University
Original Assignee
Department of Biotechnology of Ministry of Science and Technology India
Panjab University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Department of Biotechnology of Ministry of Science and Technology India, Panjab University filed Critical Department of Biotechnology of Ministry of Science and Technology India
Publication of WO2013105101A1 publication Critical patent/WO2013105101A1/en
Publication of WO2013105101A8 publication Critical patent/WO2013105101A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Solid lipid nanoparticles and the process thereof are disclosed. The solid lipid nanoparticles comprise: at least one lipid selected from the group consisting of glycerides and fatty acids, at least one hydrophilic drug or amphiphilic drug and at least one emulsifier.
PCT/IN2012/000154 2012-01-13 2012-03-05 Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same Ceased WO2013105101A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN127DE2012 2012-01-13
IN127/DEL/2012 2012-01-13

Publications (2)

Publication Number Publication Date
WO2013105101A1 WO2013105101A1 (en) 2013-07-18
WO2013105101A8 true WO2013105101A8 (en) 2014-01-30

Family

ID=48781104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000154 Ceased WO2013105101A1 (en) 2012-01-13 2012-03-05 Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same

Country Status (1)

Country Link
WO (1) WO2013105101A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306389A (en) * 2014-10-20 2015-01-28 河南牧翔动物药业有限公司 Lincomycin-spectinomycin compound nano-emulsion

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
PL3057604T3 (en) * 2013-10-14 2021-12-20 Nanosphere Health Sciences Inc. Nanoparticle compositions and methods as carriers of nutraceutical agents across cell membranes and biological barriers
CN103816111B (en) * 2014-02-26 2016-08-17 中国人民解放军第二军医大学 A kind of ropivacaine nano-lipid carrier temperature sensing in situ gel rubber and preparation method thereof
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US11707436B2 (en) 2014-12-15 2023-07-25 Nanosphere Health Sciences Inc. Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of NSAIDS
US10028919B2 (en) 2015-03-10 2018-07-24 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
MA52645B1 (en) 2015-10-22 2022-06-30 Modernatx Inc Respiratory virus vaccines
EP4039699A1 (en) 2015-12-23 2022-08-10 ModernaTX, Inc. Methods of using ox40 ligand encoding polynucleotides
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
EP3625345B1 (en) 2017-05-18 2023-05-24 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
CN109260181A (en) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 Heparin nebulization sucking pharmaceutical solutions and preparation method thereof
EP3714045A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
WO2019104152A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
US20210069121A1 (en) 2017-12-12 2021-03-11 Lead Biotherapeutics Ltd Solid lipid nanoparticle for intracellular release of active substances and method for production the same
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019200171A1 (en) 2018-04-11 2019-10-17 Modernatx, Inc. Messenger rna comprising functional rna elements
CN108484898A (en) * 2018-04-20 2018-09-04 江苏保易制药有限公司 The preparation method of polysorbate without polyoxyethylene isobide aliphatic ester
EP3796893A1 (en) 2018-05-23 2021-03-31 Modernatx, Inc. Delivery of dna
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US20220110966A1 (en) 2018-09-02 2022-04-14 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2020056161A1 (en) 2018-09-12 2020-03-19 University Of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
WO2020056147A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
MA53608A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR THE E1-ALPHA, E1-BETA AND E2 SUBUNITS OF THE BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FOR THE TREATMENT OF LEUCINOSIS
CA3112398A1 (en) 2018-09-14 2020-03-19 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
MX2021006912A (en) 2018-12-11 2021-08-24 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof.
EP3965806A1 (en) 2019-05-08 2022-03-16 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
MA56539A (en) 2019-06-24 2022-04-27 Modernatx Inc ENDONUCLEASE RESISTANT MESSENGER RNA AND USES THEREOF
US11987791B2 (en) 2019-09-23 2024-05-21 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
CN114391040A (en) 2019-09-23 2022-04-22 欧米茄治疗公司 Compositions and methods for modulating apolipoprotein B (APOB) gene expression
CN116096886A (en) 2020-03-11 2023-05-09 欧米茄治疗公司 Compositions and methods for modulating fork-box P3 (FOXP 3) gene expression
US20230235298A1 (en) 2020-06-01 2023-07-27 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
CN112120228B (en) * 2020-08-28 2024-03-26 盐城工学院 A solid lipid particle embedded with feruloyl oligosaccharide, its preparation method and its application as a food additive
AU2021377895A1 (en) 2020-11-13 2023-06-15 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
CZ309587B6 (en) * 2021-01-22 2023-05-03 Oncora S.R.O. Microemulsion preconcentrate containing cladribine and preparing it
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
JP2024512026A (en) 2021-03-24 2024-03-18 モデルナティエックス インコーポレイテッド Lipid nanoparticles and polynucleotide encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
EP4355882A2 (en) 2021-06-15 2024-04-24 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
CN114931551B (en) * 2022-05-11 2023-04-25 四川科瑞德制药股份有限公司 Miku ammonium chloride injection with storage stability at 25 ℃ and preparation method and application thereof
TW202412818A (en) 2022-07-26 2024-04-01 美商現代公司 Engineered polynucleotides for temporal control of expression
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2024182301A2 (en) 2023-02-27 2024-09-06 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024229321A1 (en) 2023-05-03 2024-11-07 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025129183A1 (en) * 2023-12-14 2025-06-19 University Of Georgia Research Foundation, Inc. Lipid nanoparticles comprising encapsulated proteins and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194760C (en) * 2003-08-28 2005-03-30 东南大学 Method for preparing nanometre structure medicine
CN1269472C (en) * 2004-10-14 2006-08-16 东南大学 Method for preparing ten nanometers level solid lipid nanometer particle
FR2885538B1 (en) * 2005-05-16 2007-08-10 Univ Claude Bernard Lyon NOVEL PROCESS FOR PREPARING SOLID LIPID PARTICLES USING A MEMBRANE REACTOR

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306389A (en) * 2014-10-20 2015-01-28 河南牧翔动物药业有限公司 Lincomycin-spectinomycin compound nano-emulsion

Also Published As

Publication number Publication date
WO2013105101A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
WO2013105101A8 (en) Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same
WO2013177421A3 (en) Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
ZA201405956B (en) Method for the preparation of triglycerides of medium-chain length fatty acids.
WO2012125987A3 (en) Delivery system
EP3398948A3 (en) 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
PT2913353T (en) Amphiphilic block copolymer and preparation method thereof and micellar drug-loading system formed by same with antitumor drug
BR112015002940A2 (en) microorganisms and methods for the production of fatty acids and products derived from fatty acids.
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
WO2012116073A3 (en) Amphiphilic dendron-coils, micelles thereof and uses
JP2013005803A5 (en)
WO2013057570A3 (en) Acrylic polymer formulations
WO2012087062A3 (en) Sustained-release polymeric microparticles containing poorly water-soluble drug and method for preparing the same
BR112015001577A2 (en) emulsifying agent, food product, method for the manufacture of a food product and emulsifying and stabilizing agent.
WO2012032416A3 (en) Comestible emulsions
BR112014026149A2 (en) Method for the preparation of 2,4-dihydroxybutyric acid (2,4-dhb) and microorganism.
EP3278799A4 (en) Docetaxol albumin nanoparticle pharmaceutical composition, preparation method therefor and use thereof
WO2015066668A8 (en) Methods of removing alpha-galactose
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
HK1216839A1 (en) Modified release formulation
WO2016193924A3 (en) System of multiple bags and method for the preparation of hemocomponents
HK1231376A1 (en) Topical formulations and uses thereof
EP3305795A4 (en) Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2013023641A3 (en) Method for producing a composition for application to the skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12864771

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 12864771

Country of ref document: EP

Kind code of ref document: A1